A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Dystonia

In brief

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Key facts

Study ID

NCT07304089

Run by

Vima Therapeutics

People needed

100

Starts

2026-02-05

Expected to finish

2027-05-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
• The participant has a clinical diagnosis of isolated dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.
• The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.
• The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

Where it is running

• Vima Site #015 — Spokane, Washington, United States (enrolling)
• Vima Site #039 — Scottsdale, Arizona, United States (enrolling)
• Vima Site #004 — Scottsdale, Arizona, United States (enrolling)
• Vima Site #028 — Sun City, Arizona, United States (enrolling)
• Vima Site #042 — Irvine, California, United States (enrolling)
• Vima Site #012 — Houston, Texas, United States (enrolling)
• Vima Site #011 — Richmond, Virginia, United States (enrolling)
• Vima Site #023 — Kirkland, Washington, United States (enrolling)
• Vima Site #033 — Birmingham, Alabama, United States (enrolling)
• Vima Site #019 — Denver, Colorado, United States (enrolling)
• Vima Site #009 — Gainesville, Florida, United States (enrolling)
• Vima Site #008 — Miami, Florida, United States (enrolling)
• Vima Site #031 — Orlando, Florida, United States (enrolling)
• Vima Site #005 — Atlanta, Georgia, United States (enrolling)
• Vima Site #027 — Chicago, Illinois, United States (enrolling)
• Vima Site #041 — Overland Park, Kansas, United States (enrolling)
• Vima Site #043 — Baltimore, Maryland, United States (enrolling)
• Vima Site #007 — Olney, Maryland, United States (enrolling)
• Vima Site #032 — Boston, Massachusetts, United States (enrolling)
• Vima Site #037 — East Lansing, Michigan, United States (enrolling)
• Vima Site #002 — Farmington Hills, Michigan, United States (enrolling)
• Vima Site #038 — St Louis, Missouri, United States (enrolling)
• Vima Site #014 — Albuquerque, New Mexico, United States (enrolling)
• Vima Site #018 — New York, New York, United States (enrolling)
• Vima Site #024 — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.